NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

COCP

Cocrystal Pharma Inc

Jun 30 • 02:45PM ET

1.49

Dollar change +0.00
Percentage change 0.27	%

Healthcare • Biotechnology • USA • NASD

Peers: MRNA BNTX GILD REGN PFE JNJ VRTX AZN NVAX SNY

| Held by: VTI VXF DFAT

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.56	Insider Own	31.67%	Shs Outstand	10.17M	Perf Week	-4.84%
Market Cap	15.20M	Forward P/E	-	EPS next Y	-1.16	Insider Trans	0.00%	Shs Float	6.95M	Perf Month	-3.92%
Enterprise Value	9.93M	PEG	-	EPS next Q	-0.30	Inst Own	7.36%	Short Float	0.07%	Perf Quarter	0.95%
Income	-15.85M	P/S	-	EPS this Y	34.88%	Inst Trans	5.23%	Short Ratio	0.24	Perf Half Y	-40.71%
Sales	0.00M	P/B	2.08	EPS next Y	-3.57%	ROA	-85.20%	Short Interest	0.00M	Perf YTD	-26.04%
Book/sh	0.72	P/C	2.17	EPS next 5Y	11.31%	ROE	-106.05%	52W High	3.26 -54.17%	Perf Year	-38.77%
Cash/sh	0.69	P/FCF	-	EPS past 3/5Y	-120.49% -2.62%	ROIC	-181.59%	52W Low	1.12 33.39%	Perf 3Y	-69.63%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.60% 7.62%	Perf 5Y	-90.57%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	5.69%	Oper. Margin	-	ATR (14)	0.11	Perf 10Y	-99.66%
Dividend Ex-Date	-	Quick Ratio	4.57	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	46.15	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.57	EPS Q/Q	41.82%	SMA20	-5.10%	Beta	2.08	Target Price	8.00
Payout	-	Debt/Eq	0.24	Sales Q/Q	-	SMA50	-2.37%	Rel Volume	1.00	Prev Close	1.49
Employees	11	LT Debt/Eq	0.19	Earnings	May 15 BMO	SMA200	-16.20%	Avg Volume	19.74K	Price	1.49
IPO	Apr 01, 2008	Option/Short	No / Yes	EPS/Sales Surpr.	54.46% -	Trades		Volume	16,940	Change	0.27%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-08-20	Initiated	H.C. Wainwright	Buy	$5

Jun-05-25 08:00AM	Cocrystal Pharma's Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference (GlobeNewswire)
May-29-25 08:00AM	Cocrystal Pharma's Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain (GlobeNewswire) +8.74%
May-28-25 08:00AM	Cocrystal Pharma to Participate in Noble Capital Markets' 2025 Emerging Growth Virtual Equity Conference (GlobeNewswire)
May-15-25 08:00AM	Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs (GlobeNewswire)
Apr-24-25 08:00AM	Cocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants (GlobeNewswire)
08:00AM	Loading…
Apr-16-25 08:00AM	Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference (GlobeNewswire)
Mar-31-25 08:00AM	Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs (GlobeNewswire)
Mar-14-25 08:35AM	Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire)
Mar-12-25 01:12PM	Life Sciences Investor Forum Agenda Announced for March 13th (GlobeNewswire)
Mar-06-25 08:00AM	Cocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025 (GlobeNewswire)
Jan-08-25 08:00AM	Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections (GlobeNewswire) +6.50%
Jan-02-25 06:34AM	Cocrystal to extend enrolment in Phase IIa influenza inhibitor trial (Clinical Trials Arena) +14.85%
Dec-31-24 02:03PM	Cocrystal Pharma Shares Drop 35% Following Phase 2a Study Extension Announcement (GuruFocus.com) -37.85%
08:00AM	Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344 (GlobeNewswire)
Nov-13-24 08:00AM	Cocrystal Pharma Reports Third Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs (GlobeNewswire)
08:00AM	Loading…
Oct-31-24 08:00AM	Cocrystal Pharma's Co-CEOs Highlight Pioneering Approach to Antiviral Drug Candidates Targeting Influenza and Coronaviruses as Fall Flu and COVID Season Begins (GlobeNewswire)
Sep-26-24 08:00AM	Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 into Phase 1 Multiple-Ascending Dose Cohorts (GlobeNewswire)
Aug-19-24 04:05PM	Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences (GlobeNewswire) +15.38% -9.05%
Aug-15-24 03:00PM	CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event (ACCESSWIRE)
Aug-14-24 08:00AM	Cocrystal Pharma Reports Second Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs (GlobeNewswire) -10.53%
Jul-18-24 08:00AM	Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor (GlobeNewswire)
Jun-20-24 08:00AM	New Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected Dairy Cows (GlobeNewswire)
Jun-07-24 09:55AM	Cocrystal Pharma, Inc. (COCP) Now Trades Above Golden Cross: Time to Buy? (Zacks)
May-13-24 01:53PM	COCP Stock Earnings: Cocrystal Pharma Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs (GlobeNewswire)
May-01-24 08:00AM	Enrollment Completed in Phase 2a Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza (GlobeNewswire)
Mar-28-24 01:53PM	COCP Stock Earnings: Cocrystal Pharma Beats EPS for Q4 2023 (InvestorPlace) -6.67%
08:00AM	Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs (GlobeNewswire)
Mar-19-24 08:00AM	Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A (GlobeNewswire)
Mar-05-24 08:30AM	Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap (ACCESSWIRE)
08:00AM	Loading…
Jan-04-24 08:00AM	Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates (GlobeNewswire)
Dec-06-23 08:00AM	Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A (GlobeNewswire)
Nov-29-23 08:00AM	Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast (GlobeNewswire)
Nov-27-23 08:00AM	Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023 (GlobeNewswire) +17.12%
Nov-13-23 08:00AM	Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs (GlobeNewswire)
Nov-09-23 08:00AM	Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast (GlobeNewswire)
Oct-31-23 08:00AM	Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344 (GlobeNewswire) +5.25%
Oct-02-23 12:14PM	COCP: Cocrystal Pharma doses 1st subjects in the important CDI-988 clinical trial. (Zacks)
Sep-28-23 08:00AM	Cocrystal Pharma Doses First Subjects in Clinical Study of CDI-988 For Pandemic Norovirus and Coronavirus (GlobeNewswire)
Sep-05-23 08:00AM	Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference (GlobeNewswire) -8.38%
Aug-16-23 09:11AM	COCP: Cocrystal Pharma reports 2nd quarter 2023 financial results and provides updates on drug pipeline. (Zacks)
Aug-14-23 08:00AM	Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs (GlobeNewswire)
Aug-08-23 08:00AM	Cocrystal Pharma Selects Novel Oral Protease Inhibitor CDI-988 as Norovirus Lead (GlobeNewswire) +7.39%
May-31-23 08:00AM	Cocrystal Pharma Receives HREC Approval to Initiate Phase 1 Study to Evaluate Oral Broad-Spectrum Coronavirus 3CL Protease Inhibitor CDI-988 (GlobeNewswire)
May-17-23 09:26AM	COCP: Cocrystal Pharma reports 1st quarter 2023 financial results and provides updates on drug pipeline. (Zacks Small Cap Research) -5.88%
May-15-23 08:00AM	Cocrystal Pharma Reports First Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs (GlobeNewswire) -5.28%
May-04-23 04:05PM	Cocrystal Pharma Presents New Data from its CC-42344 Phase 1 Influenza A Study at the 7th Annual ISIRV Antiviral Group Conference (GlobeNewswire)
Apr-24-23 08:00AM	Cocrystal Pharma Appoints Pharma Industry Veteran Fred Hassan to its Board of Directors (GlobeNewswire) +6.05%
Apr-18-23 08:00AM	Cocrystal Pharma to Present New Data from its CC-42344 Phase 1 Influenza A Study at the 7th Annual ISIRV Antiviral Group Conference (GlobeNewswire)
Apr-10-23 08:30AM	Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) +12.95%
Mar-31-23 10:05AM	COCP: UPDATE: Cocrystal Pharma announces full year 2022 financial results and provides drug program updates. (Zacks Small Cap Research) +5.85%
Mar-29-23 08:00AM	Cocrystal Pharma Reports 2022 Financial Results and Provides Updates on its Antiviral Drug Development Programs (GlobeNewswire)
Mar-22-23 01:03PM	COCP: UPDATE: Cocrystal Pharma announced several program updates and investor events. (Zacks Small Cap Research)
08:00AM	Cocrystal Pharma to Highlights Progress with Its Antiviral Portfolio at the Virtual Investor Summit on March 29, 2023 (GlobeNewswire)
Jan-26-23 08:00AM	Cocrystal Pharma Announces Participation in Virtual Investor Events (GlobeNewswire) -6.62%
Jan-23-23 09:00AM	Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day Podcast (Newsfile)
Dec-19-22 08:00AM	Cocrystal Pharma Reports Highly Favorable Safety and Tolerability Results from a Phase 1 Study with its Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A (GlobeNewswire) -11.39%
Dec-01-22 04:05PM	Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022 (GlobeNewswire)
Nov-17-22 01:38PM	Cocrystal Pharma Posts Favorable Safety Data From Oral Antiviral Against Influenza A (Benzinga)
08:00AM	Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A (GlobeNewswire)
Nov-15-22 11:19AM	COCP: UPDATE: Cocrystal Pharma releases 2022 3rd quarter results and provides an update on the current pipeline programs. (Zacks Small Cap Research)
Nov-14-22 08:00AM	Cocrystal Pharma Reports Third Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs (GlobeNewswire)
Nov-02-22 08:00AM	Cocrystal Pharma to Participate in Two Investor Conferences in November (GlobeNewswire) +13.41%
Nov-01-22 04:05PM	Cocrystal Pharma Granted European Patent Covering Oral Antiviral Candidate CC-42344 in Combination with Another Antiviral Agent for the Treatment of Influenza (GlobeNewswire)
Oct-26-22 08:00AM	Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharmas Oral Antiviral Candidate CC-42344 (GlobeNewswire)
Oct-19-22 08:00AM	Cocrystal Pharma to Present at the LD Micro Main Event XV (GlobeNewswire)
Oct-13-22 08:00AM	Cocrystal Pharma to Present CC-42344 Phase 1 Influenza A Data at the World Antiviral Congress 2022 (GlobeNewswire)
Oct-11-22 11:51AM	Cocrystal Pharma Advances One Of Its COVID-19 Antiviral Treatment Candidate (Benzinga) -9.02%
08:00AM	Cocrystal Pharma Selects CDI-988 for Clinical Development as an Oral Treatment for COVID-19 (GlobeNewswire)
Oct-05-22 08:00AM	Cocrystal Pharma to Present at the Dawson James Securities 2022 Small Cap Growth Conference (GlobeNewswire)
Oct-03-22 04:05PM	Cocrystal Pharma Announces a 1-for-12 Reverse Stock Split (GlobeNewswire) -13.65%
Sep-06-22 10:05AM	Companies Like Cocrystal Pharma (NASDAQ:COCP) Are In A Position To Invest In Growth (Simply Wall St.)
08:00AM	Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-19-22 08:10AM	COCP: UPDATE: Cocrystal Pharma releases 2022 2nd quarter results and provides an update on the current pipeline programs. (Zacks Small Cap Research) -6.42%
Aug-15-22 08:00AM	Cocrystal Pharma Reports Second Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs (GlobeNewswire)
Aug-08-22 08:00AM	Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344 (GlobeNewswire)
Aug-03-22 09:00AM	Cocrystal Pharma Discusses Therapeutic Platform Applications and Progress with The Stock Day Podcast (Newsfile)
Jul-14-22 08:00AM	Cocrystal Pharma Reports CC-42344 Pharmacokinetic Data in Influenza A Once-Daily Dosing (GlobeNewswire)
Jun-01-22 08:00AM	Cocrystal Pharma Expands Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors (GlobeNewswire)
May-18-22 08:00AM	Cocrystal Pharma to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire)
May-12-22 08:12AM	COCP: Cocrystal Pharma Releases 2022 1st Quarter Results and Provides an Update on the Current Pipeline Programs (Zacks Small Cap Research)
May-11-22 08:00AM	Cocrystal Pharma Reports First Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs and Milestones (GlobeNewswire) -5.02%
Apr-21-22 08:00AM	Cocrystal Pharma Collaborates with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors (GlobeNewswire)
Apr-19-22 08:00AM	Cocrystal Pharma to Present at the Life Science Innovation Northwest 2022 Conference (GlobeNewswire)
Apr-14-22 08:00AM	Cocrystal Pharma to Present at the Noble Capital Markets NobleCon18 Conference (GlobeNewswire)
Apr-12-22 11:01AM	Cocrystal Pharma Posts Favorable Preliminary Data From Influenza A Antiviral Candidate Trial (Benzinga)
08:00AM	Cocrystal Pharma Reports Favorable Preliminary Data from Phase 1 Initial Cohorts with CC-42344, a Novel, Broad-Spectrum Influenza A antiviral (GlobeNewswire)
Apr-06-22 10:15AM	10 Biotech Penny Stocks with Growth Catalysts (Insider Monkey)
Mar-30-22 02:57PM	We're Hopeful That Cocrystal Pharma (NASDAQ:COCP) Will Use Its Cash Wisely (Simply Wall St.)
Mar-25-22 07:30AM	COCP: Cocrystal Pharma releases 2021 fiscal year results and provides an update on the current pipeline programs (Zacks Small Cap Research)
Mar-23-22 04:05PM	Cocrystal Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones (GlobeNewswire)
Mar-22-22 08:00AM	Cocrystal Pharma to Participate in the Maxim Group 2022 Virtual Growth Conference (GlobeNewswire)
Mar-10-22 08:00AM	Cocrystal Pharma Initiates Enrollment in Phase 1 Influenza A Study with Novel, Broad-Spectrum, Orally Administrated Antiviral CC-42344 (GlobeNewswire)
Mar-03-22 08:00AM	Cocrystal Pharma to Participate in Upcoming Investment Conferences (GlobeNewswire)
Feb-24-22 08:10AM	COCP: Cocrystal Pharma has secured funding to enter three clinical trials and fund planned operations through 2023 (Zacks Small Cap Research)
Jan-27-22 12:22PM	Cocrystal Pharma To Develop Additional Two Antiviral Drug Candidates For COVID-19 (Benzinga)
08:00AM	Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program (GlobeNewswire)
Jan-11-22 07:00AM	SomaLogic Announces Preliminary Revenue for Full Year 2021 Above Guidance Range (GlobeNewswire)
Jan-10-22 04:10PM	SomaLogic Announces Appointment of Adam Taich as Chief Business Officer (GlobeNewswire)
Jan-06-22 08:00AM	Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205 (GlobeNewswire)

Cocrystal Pharma, Inc. is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. It focuses on the preclinical and early clinical stage antiviral compounds for unmet medical needs including influenza, Hepatitis C virus, and norovirus infections. The company was founded in 2008 and is headquartered in Bothell, WA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

COCP

Cocrystal Pharma Inc

Upgrade your FINVIZ experience